RusnanoMedInvest specializes in investing in the development of innovative pharmaceutical technologies and products in Russia and worldwide.
We are interested in investment opportunities in promising new developments in the field of pharmaceuticals and medical equipment;
Our investment strategy and focus centers primarily around projects at the later stages of development, in particular compounds or products that have proven, market-relevant differentiated therapeutic efficacy, tolerability or safety in phase 2 or later or otherwise demonstrate game-changing potential with respect to patient welfare or healthcare economics.
Our portfolio companies:
Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public offering. All of the shares in the proposed offering are to be sold by Syndax.
17 May 2017
17 May 2017
Celtaxsys announces full enrollment of its landmark EMPIRE-CF phase 2b clinical trial assessing the potential of novel anti-inflammatory investigational therapy, oral acebilustat, to preserve lung function in CF patients
16 May 2017